Powering what's possible
in research & development
Guided by Purpose: Reimagined Mission, Vision and Values
We believe that innovation, collaboration and technology must work hand-in-hand to create meaningful change. At Novavax, we are stepping into the future with a renewed sense of purpose—one that reflects not just what we do but why we do it.
Novavax Reports CIC and Stand-alone Influenza Phase 3 Trial Results
Novavax’s COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial
U.S. FDA Approves BLA for Nuvaxovid™, Novavax’s COVID-19 Vaccine
Biologics License Application (BLA) approval triggers $175 million Sanofi milestone payment, with additional COVID-19 vaccine milestones and ongoing tiered royalties to be recognized when earned.
A Proven PlatformOur proprietary cutting-edge technology platform is revolutionizing the development of vaccines to help prevent some of the world's most challenging diseases.
Our strategy is to create partnership and collaboration opportunities to maximize the impact and value of our pipeline assets and Matrix-M alone.
Keep up to date on the latest happenings at Novavax as we tackle the world’s most significant health needs.
Learn about and sign up for investor updates, including event notifications, daily stock prices, SEC filings and press releases.
RetroSearch is an open source project built by @garambo | Open a GitHub Issue
Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo
HTML:
3.2
| Encoding:
UTF-8
| Version:
0.7.4